CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Biocompatibility Studies On CHO Cell Culture In X-ray Irradiated BioBLU® Single-Use Bioreactors

  In cell culture, the leakage of toxic or inhibitory chemicals from single-use bioreactors has become a growing concern. Explore recommendations for leachable studies.

• Optimized Product Recovery Using The Drug Product Filtration System

  Explore strategies to maximize drug product recovery during sterile filtration, minimize hold-up volume, and reduce dilution after PUPSIT to ensure higher yield, improved efficiency, and less waste.

• NDA Success Strategy: Using Non-US Clinical Data In An NDA Submission

  A sponsor acquiring a therapeutic asset from an overseas company sought assistance when including foreign clinical trial dat,a generated outside a U.S. IND, in a New Drug Application (NDA).

• Quantifying Lentiviral Physical Titer Using The QIAcuity dPCR System

  Streamline lentiviral vector analytics with our direct RT-dPCR method. Achieve precise, reproducible results to accelerate safe, effective gene therapies with enhanced quality control.

• How Lipid Nanoparticles Enable Next-Gen Delivery

  Cell therapy’s future depends on smarter gene delivery. Learn how lipid nanoparticles offer a scalable, cell-friendly alternative to electroporation and viral vectors for manufacturing efficiency.

• Economic Advantage Of Robotic Gloveless Pharmaceutical Isolators

  Are robotic gloveless isolators the key to smarter, safer, scalable solutions? Discover how they can revolutionize aseptic filling by reducing contamination, minimizing waste, and enhancing manufacturing flexibility.

• Leveraging Integrated Media Services For Speed And Efficiency

  Uncertainty in media stability can limit efficiency and scalability in biologics manufacturing. See how a data-driven approach enables more predictable planning and reduces operational strain.

• Revolutionizing Lentiviral Vector Manufacturing For In Vivo, Ex Vivo CAR-T Therapies

  Discover how scalable, cost-effective, and high-quality lentiviral vector manufacturing can accelerate both ex vivo and emerging in vivo CAR-T therapies.

• Single-Use Innovation For The Future Of Therapeutic Manufacturing

  Gain insight into these end-to-end plasmid DNA solutions, leveraging robust cGMP-compliant processes and single-use manufacturing platforms to accelerate your cell and gene therapy programs.

• Simplified LV And AAV Clarification With TFDF-Based Intensified Virus Production

  Learn how Tangential Flow Depth Filtration (TFDF) enhances viral vector production, streamlining the clarification process and increasing efficiency and yield for LV and AAV manufacturing.